Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Insilico Medicine Announces US$888M Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

January 4, 2026

Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates

January 4, 2026

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

January 4, 2026

BioAtla and GATC Health Announce a $40M SPV Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ OPSCC

January 4, 2026

AbbVie secured global rights outside China to ZG006 (alveltamig) developed by Suzhou Zelgen Biopharmaceuticals

January 4, 2026

Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates

December 30, 2025

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly 

December 30, 2025

Oncodesign Precision Medicine and Navigo Proteins announce the end of their collaboration in the development of radiotheranostics

December 30, 2025

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

December 30, 2025

Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial of bexmarilimab + zimberelimab 

December 30, 2025

Athira Pharma Announces Exclusive License to Lasofoxifene Ph 3 Development Program for Metastatic Breast Cancer Candidate and Financing for up to $236M

December 30, 2025

LIXTE Biotechnology, The University of Texas MD Anderson Cancer Center, and GSK expand collaboration on LB-100 to treat ovarian clear cell cancer

December 30, 2025

GMP Manufacturing of AKTX-101 ADC Program Initiated to Support Ph 1 First-in-Human Clinical Trial

December 30, 2025

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

December 22, 2025

Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need

December 22, 2025

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with BMS to Discover and Develop Next-Gen Multi-Specific Antibodies

December 22, 2025

Trethera Receives $2.7M NIH Grant for TRE-515 to Overcome KRAS Inhibitor Resistance in Lung Cancer

December 22, 2025

Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program

December 22, 2025

Orum Therapeutics Secures ~US$100M to Accelerate Development of Leading Degrader ADC Programs to Treat Serious Diseases

December 22, 2025

University of Chicago Extends Collaboration with AbbVie to Advance Clinical Research and Patient Outcomes in Oncology

December 22, 2025

Athira Pharma Announces Exclusive License to Lasofoxifene Ph 3 Development Program for Metastatic Breast Cancer Candidate and Financing for up to $236M

December 22, 2025

Pan Cancer T Secures EUR 10M to Advance First-in-Human Trial of PCT1:CO-STIM in TNBC

December 15, 2025

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

December 15, 2025

Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

December 15, 2025

D3 Bio Secures $108M in Series B Financing to Advance Global Clinical Programs

December 15, 2025
Page1 … Page4 Page5 Page6 Page7 Page8 … Page42

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.